Part II: How to Overcome Resistance to Venetoclax According to Marina Konopleva, MD, PhD
By Leah Sherwood - Last Updated: November 15, 2022In the second video of a series with Marina Konopleva, MD, PhD, recorded during the 2022 SOHO Annual Meeting, she discusses venetoclax resistance in acute myeloid leukemia (AML).
Advertisement
Post Tags:SOHO 2022
Advertisement
Related Posts
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Clinical development of AUTX-703 is planned to begin in the first quarter of 2025.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
The amended protocol includes reducing the size of the MIRACLE trial by approximately 10%.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.